Joseph Monahan is CSO at Aclaris Therapeutics, Inc. (ACRS). They have made 8 open-market trades across 1 company since 2021, most recently 2025-03-01.
CIK 0001861790
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ACRS | 281,995 | $1.0M |
Shares reported on the most recent Form 4, priced at the 2025-03-04 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ACRS | SELL · 10b5-1 | 2023-10-23 | 2023-10-25 | $5.08 | $30K | +18.4% | -81.9% | -72.4% |
| ACRS | SELL · 10b5-1 | 2023-08-21 | 2023-08-22 | $7.32 | $44K | +4.5% | -9.8% | -87.6% |
| ACRS | SELL · 10b5-1 | 2023-06-20 | 2023-06-22 | $10.28 | $123K | +5.1% | -3.0% | -33.3% |
| ACRS | SELL | 2023-03-02 | 2023-03-03 | $12.55 | $588K | +5.1% | +13.6% | +14.5% |
| ACRS | SELL | 2023-02-15 | 2023-02-17 | $13.06 | $65K | -2.5% | -38.6% | -37.3% |
| ACRS | SELL | 2022-12-15 | 2022-12-16 | $15.88 | $79K | +4.4% | +15.9% | -47.4% |
| ACRS | SELL | 2022-10-17 | 2022-10-19 | $15.98 | $80K | -2.4% | +14.8% | +11.9% |
| ACRS | SELL | 2022-04-18 | 2022-04-20 | $16.28 | $977K | -18.1% | -23.5% | +1.8% |
| ACRS | SELL | 2022-03-10 | 2022-03-14 | $15.71 | $854K | +23.1% | +9.4% | -9.7% |
| ACRS | SELL | 2022-02-09 | 2022-02-11 | $12.68 | $5K | +11.8% | +14.0% | -19.4% |
| ACRS | SELL | 2021-06-02 | 2021-06-02 | $21.73 | $551K | -18.1% | -21.6% | -25.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.